1157 Modified Release Phosphatidylcholine LT-02 in Active Ulcerative Colitis - a Randomized, Placebo-Controlled Multicentre Study

New therapeutic avenues in ulcerative colitis: thinking out of the box

“…Finally, the results of a phase IIb placebo-controlled dose-finding study with an optimised highly enriched PC preparation (LT-02; 0.8 g, 1.6 g and 3.2 g) in 156 patients with mesalazine-refractory UC were recently presented. Remission rates doubled in the highest dose group compared with placebo (31.4% vs 15%) and an overall improvement in endoscopic disease activity measured by mucosal healing, as well as an earlier time to symptom resolution, was found in patients receiving LT-02 treatment 34 35…”

Lipid antigens in immunity

“…Further, a variety of genes with critical roles in lipid metabolism have been highlighted by expression analysis and genome-wide association studies in IBD and may at least partially contribute to disease susceptibility through modulation of the activation of lipid-reactive T cells (Jostins et al, 2012; Planell et al, 2013). Finally, a randomized, placebo-controlled, multicenter study recently revealed the efficacy of oral PC in UC (Karner et al, 2012). Given that PC binds to CD1d but does not activate human NKT cells (Fox et al, 2009), interference with CD1d-restricted mucosal NKT cell activation may contribute to the therapeutic efficacy of PC, a concept that awaits verification.…”